Cypherpunk Technologies (NASDAQ:CYPH) Issues Quarterly Earnings Results

Cypherpunk Technologies (NASDAQ:CYPH) posted its quarterly earnings data on Thursday. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.42), FiscalAI reports.

Cypherpunk Technologies Stock Up 15.4%

Shares of CYPH traded up $0.16 on Thursday, reaching $1.20. The stock had a trading volume of 5,738,842 shares, compared to its average volume of 3,743,656. The firm has a market capitalization of $117.22 million, a PE ratio of 17.14 and a beta of -0.09. The firm has a 50-day moving average of $0.83 and a 200 day moving average of $0.99. Cypherpunk Technologies has a twelve month low of $0.23 and a twelve month high of $3.70.

Institutional Investors Weigh In On Cypherpunk Technologies

A number of institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC acquired a new stake in Cypherpunk Technologies during the 4th quarter valued at $37,000. LPL Financial LLC acquired a new stake in Cypherpunk Technologies during the 4th quarter valued at $38,000. HighTower Advisors LLC acquired a new stake in Cypherpunk Technologies during the 4th quarter valued at $59,000. State Street Corp acquired a new stake in Cypherpunk Technologies during the 4th quarter valued at $163,000. Finally, Acadian Asset Management LLC grew its holdings in Cypherpunk Technologies by 470.4% during the 1st quarter. Acadian Asset Management LLC now owns 1,280,531 shares of the company’s stock valued at $389,000 after buying an additional 1,056,047 shares during the last quarter. Institutional investors and hedge funds own 30.46% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Cypherpunk Technologies from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Cypherpunk Technologies Company Profile

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.